Clinical effect of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome

中国基层医药 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.06.020

Yuanyuan Chen, Qin Liu, Qilan Chen, Jia Zhou

{"title":"Clinical effect of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome","authors":"Yuanyuan Chen, Qin Liu, Qilan Chen, Jia Zhou","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.06.020","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical efficacy and safety of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome. \n \n \nMethods \nFrom June 2014 to June 2015, 126 elderly patients with primary hyperlipidemia of phlegm and blood stasis syndrome admitted to Hangzhou Hospital of Traditional Chinese Medicine were randomly divided into control group and observation group, with 63 cases in each group.The patients in the control group were given basic treatment plus atorvastatin calcium tablets, and the patients in the observation group were treated with Zhibitai capsule on the basis of the control study.Both two groups received continuous treatment for 12 weeks.The clinical efficacy, TCM syndrome integral, blood lipid, hemorheology and adverse reactions of the two groups were observed. \n \n \nResults \nThe total effective rate in the observation group was 92.1%(58/63), which was higher than 81.0%(51/63) in the control group, and the difference was statistically significant(χ2=8.199, P 0.05). \n \n \nConclusion \nZhibitai capsule can effectively improve the clinical efficacy, improve TCM syndromes, reduce blood lipids and improve hemorheology parameters in elderly patients with hyperlipidemia syndrome of phlegm and blood stasis syndrome, with no obvious adverse reactions, which is worthy of clinical promotion. \n \n \nKey words: \nHyperlipidemia; Senile; Phlegm and blood stasis syndrome; Zhibitai capsule; Chinese patent medicine; Hemorheology; Clinical efficacy; Blood lipid","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"733-737"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.06.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the clinical efficacy and safety of Zhibitai capsule in the treatment of senile hyperlipidemia patients with phlegm and blood stasis syndrome. Methods From June 2014 to June 2015, 126 elderly patients with primary hyperlipidemia of phlegm and blood stasis syndrome admitted to Hangzhou Hospital of Traditional Chinese Medicine were randomly divided into control group and observation group, with 63 cases in each group.The patients in the control group were given basic treatment plus atorvastatin calcium tablets, and the patients in the observation group were treated with Zhibitai capsule on the basis of the control study.Both two groups received continuous treatment for 12 weeks.The clinical efficacy, TCM syndrome integral, blood lipid, hemorheology and adverse reactions of the two groups were observed. Results The total effective rate in the observation group was 92.1%(58/63), which was higher than 81.0%(51/63) in the control group, and the difference was statistically significant(χ2=8.199, P 0.05). Conclusion Zhibitai capsule can effectively improve the clinical efficacy, improve TCM syndromes, reduce blood lipids and improve hemorheology parameters in elderly patients with hyperlipidemia syndrome of phlegm and blood stasis syndrome, with no obvious adverse reactions, which is worthy of clinical promotion. Key words: Hyperlipidemia; Senile; Phlegm and blood stasis syndrome; Zhibitai capsule; Chinese patent medicine; Hemorheology; Clinical efficacy; Blood lipid

查看原文本刊更多论文

止痹泰胶囊治疗老年高脂血症痰瘀证的临床疗效观察

目的探讨止痹泰胶囊治疗老年高脂血症痰瘀证的临床疗效和安全性。方法选取2014年6月~ 2015年6月杭州市中医院收治的老年原发性高脂血症痰瘀证患者126例，随机分为对照组和观察组，每组63例。对照组患者在基础治疗的基础上加用阿托伐他汀钙片，观察组患者在对照研究的基础上加用止痹泰胶囊。两组均连续治疗12周。观察两组患者的临床疗效、中医证候积分、血脂、血液流变学及不良反应。结果观察组总有效率为92.1%(58/63)，高于对照组81.0%(51/63)，差异有统计学意义(χ2=8.199, p0.05)。结论止痹泰胶囊能有效提高老年高脂血症痰瘀证证患者的临床疗效，改善中医证候，降低血脂，改善血液流变学参数，且无明显不良反应，值得临床推广。关键词:高脂血症;老年;痰瘀证;Zhibitai胶囊;中成药;血液流变学;临床疗效;血脂

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.